Sono-Tek Corp Dossier - Source-backed chat

Sono-Tek Corp

SOTKNASDAQ

SectorInformation Technology

IndustryElectronic Equipment and Instruments

Beta (adjusted)0.32

Intrinsic Value $4.92median of 3 methodsbased on filings through 31 May 2026

Market Price $5.82Price as of 1 Oct 2026

OvervaluedIntrinsic value is 15% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $91.5M

Enterprise Value $82.5M

Shares Outstanding 15.7M diluted

Moat Rating Wide

Next Earnings Date14 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sono-Tek Corporation (SOTK) is successfully executing a high-value strategic transition from selling individual ultrasonic nozzles and components to delivering complex, complete machine solutions and high-ASP (Average Selling Price) subsystems. This shift is driving significant margin expansion, with gross margins reaching 51% and operating income growing 81% in fiscal 2026. Despite a temporary policy-driven slowdown in the alternative energy sector, robust 54% growth in the medical device coating market and a solid $9.12 million backlog provide strong near-term visibility and support a positive outlook for the first half of fiscal 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$7.50

High · most bullish analyst$10.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

A prolonged downturn in clean energy capital expenditures, combined with a slowdown in medical device manufacturing approvals, severely impacts order intake. High customer concentration (with one customer representing 28% of sales) leads to a significant revenue drop if that key account reduces spending.

Base CaseCentral scenario

$7.5050%

Matches the consensus mean

Sono-Tek achieves flat to modestly higher revenue in fiscal 2027, supported by its $9.12 million backlog and steady medical sector demand. Gross margins remain stable at around 50-51% as the product mix continues to favor high-ASP integrated systems. Clean energy remains soft but is offset by electronics and medical growth.

Bull CaseUpside scenario

$10.0030%

The medical device sector continues to expand rapidly, driven by high-volume diagnostic and stent coating system orders. Simultaneously, clean energy policies stabilize globally, leading to a swift rebound in solar and fuel cell system demand. Operating leverage kicks in, pushing operating margins above 12%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Successful strategic transition to high-ASP, complete machine solutions driving gross margin expansion to 51%.
Strong balance sheet with $14.8 million in cash and marketable securities and zero debt, providing excellent financial flexibility.
Robust growth in the medical device end market (+54% YoY in FY 2026), offsetting cyclical softness in alternative energy.
Consistent profitability with fiscal 2026 marking the 16th consecutive year of profitable operations.

Key Investment Risks

High customer concentration, with a single customer accounting for approximately 28% of net sales in fiscal 2026.
Cyclicality and policy risk in the alternative energy sector, which caused a 19% revenue decline in that segment in FY 2026.
Limited long-term visibility beyond the first half of fiscal 2027 due to macroeconomic uncertainties and the timing of large capital orders.

Thesis Invalidation Triggers

Loss of or a material reduction in orders from the company's largest customer (representing 28% of sales).
Gross margin compression falling back below 47% due to unfavorable product mix or pricing pressure.
A persistent decline in the order backlog below $7.5 million, indicating a slowdown in new business acquisition.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.